Guselkumab as a Successful Fourth-Line Therapy
References
- Kerut CK, Wagner MJ, Daniel CP, Fisher C, Henderson EJ, Burroughs CR, et al. Guselkumab, a novel monoclonal antibody inhibitor of the p19 subunit of IL-23, for psoriatic arthritis and plaque psoriasis: a review of its mechanism, use, and clinical effectiveness. Cureus. 2023;15 (12):e51405.
- Schwensen JFB, Nielsen VW, Nissen CV, Sand C, Gniadecki R, Thomsen SF. Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study. J Eur Acad Dermatol Venereol . 2021;35 (5): e341-3.
- Ducourau E, Rispens T, Samain M, Dernis E, Le Guilchard F, Andras L, et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open. 2020;6(1):e001047.
- van Huizen A, Bank P, van der Kraaij G, Musters A, Busard C, Menting S, et al. Quantifying the effect of methotrexate on adalimumab response in psoriasis by pharmacokinetic–pharmacodynamic modeling. J Invest Dermatol. 2024;144(4):794-801.e6.
- Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, et al. A phase 2 trial of guselkumab versus ada limumab for plaque psoriasis. N Engl J Med. 2015; 373(2):136-44.
- Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76 (3):418-31.
- Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf. 2005;4(4):637-41.
- Diels J, Thilakarathne P, Cameron C, McElligott S, Schubert A, Puig L. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. Br J Dermatol. 2020;183(2):276-84.
- Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114-23.
- Thilakarathne P, Schubert A, Peterson S, Noel W, Patel BP, Hassan F. Comparing efficacy of guselkumab versus ustekinumab in patients with psoriatic arthritis: an adjusted comparison using individual patient data from the DISCOVER and PSUMMIT trials. Rheumatol Ther. 2024;11(2):457-74.
- Blauvelt A, Armstrong AW, Langley RG, Gebauer K, Thaçi D, Bagel J, et al. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. J Dermatolog Treat. 2022;33(4):2317-24.
- Song GG, Lee YH. Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: a network meta-analysis. Int J Clin Pharmacol Ther. 2021;59(6):433-41.
- Teeple A, Fitzgerald T. Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis. J Dermatolog Treat. 2022;33(1):518-24.
Language: English
Page range: 25 - 30
Submitted on: Nov 9, 2025
Accepted on: Nov 12, 2025
Published on: Aug 19, 2026
Published by: Serbian Association of Dermatovenereologists (SAD)
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Anđela Kovčić, Branislav Lekić, Marko Demenj, Svetlana Popadić, published by Serbian Association of Dermatovenereologists (SAD)
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.